Precision BioSciences, Inc.

NASDAQ:DTIL

Biotechnology

Healthcare
$7.10 +1.69%

+$0.11 today

Market cap
$198.34M
Beta
1.28
P/E (TTM)
-1.9
EPS (TTM)
-$3.47
52W Low $3.53High $8.82

Volume 0.37M

Average 0.31M

DTIL Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Precision BioSciences, Inc.NASDAQ: DTIL

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns negative

Q1 FY2026 accounts receivables was -$4M, compared with $1.69M a year earlier. Trailing-twelve-month accounts receivables was -$5.47M.

Context

  • Accounts receivables amounted to 0.7% of revenue in FY2025, down 14.5 pp from a year earlier.
  • Accounts receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly accounts receivables holds near -$4M or moves back toward the trailing-twelve-month quarterly average of -$1.37M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4M+173.0% QoQ
Last fiscal yearDec 2025
$229K-97.8% YoY
LTMMar 2026
-$5.47M-147.5% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-336.1%——
1 year-97.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
229K USD
Year-over-year change
-97.8%
4-year CAGR
-60.6%

Accounts Receivables vs competitors

How DTIL compares with its peers on the latest reported figures

  • DTIL's LTM Mar 2026 accounts receivables of $5.47M is the largest of the 7 companies compared; the peer median is $0.
  • Its year-over-year change of -147.5% is the lowest of 3, against a peer median of -61.3%.
  • Accounts receivables amounts to 12.1% of revenue for DTIL, versus a peer median of 0.0%.
DTIL Competitors Peer median
Accounts Receivables for DTIL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DTILPrecision BioSciences, Inc.LTM Mar 2026$5.47M -147.5%—12.1%
HRTXHeron Therapeutics, Inc.LTM Mar 2026$4.96M -63.0%-13.5%3.3%
GOSSGossamer Bio, Inc.LTM Mar 2026$2.67M -59.5%—4.8%
ALECAlector, Inc.LTM Mar 2026$0 ——0.0%
QTTBQ32 Bio Inc.LTM Mar 2026$0 ——0.0%
RNAAtrium Therapeutics, Inc.FY2025$0 ——0.0%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$0 ———
Peer median (excluding DTIL) $0-61.3%-13.5%0.0%

Competitors are the stored peer set for DTIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(30.6M)(111.64M)(61.32M)7.17M(45.72M)
Depreciation & Amortization10.2M9M8.26M4.58M2.75M
Deferred Income Tax00000
Stock-Based Compensation16.51M19.2M14.04M12.6M10.19M
Change in Working Capital19.58M24.11M(41.49M)(54M)(24.71M)
Accounts Receivables9.51M(232K)(181K)10.42M229K
Inventory00000
Accounts Payables867K153K1.51M(2.1M)(737K)
Other Working Capital9.21M24.19M(42.81M)(62.33M)(24.2M)
Other Non-Cash Items(26.55M)13.57M(3.6M)(28.79M)(8.35M)
Operating Cash Flow(10.85M)(45.75M)(84.11M)(58.45M)(65.84M)
Capital Expenditures(5.8M)(3.32M)(2.28M)(250K)(85K)
Acquisitions (Net)008M60K0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(750K)0107K(25K)(549K)
Investing Cash Flow(5.8M)(3.32M)5.83M(215K)(634K)
Debt Repayment2.47M19.81M0(37K)0
Common Stock Issued60.48M74.35M4.99M50.24M95.16M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities7.57M835K401K249K0
Financing Cash Flow70.52M94.99M5.39M50.45M95.16M
Effect of Forex Changes00000
Net Change in Cash53.87M45.91M(72.9M)(8.21M)28.69M
Free Cash Flow(16.66M)(49.07M)(86.39M)(58.7M)(65.93M)

Precision BioSciences, Inc.

NASDAQ:DTIL

Intrinsic Alpha fair value

Locked

Current Price

$7.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.